Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01844986
Other study ID # D0818C00001
Secondary ID 2013-001551-13
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date August 26, 2013
Est. completion date August 29, 2028

Study information

Verified date May 2024
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy.


Description:

A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 450
Est. completion date August 29, 2028
Est. primary completion date May 17, 2018
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 130 Years
Eligibility Inclusion Criteria: - Female patients with newly diagnosed, histologically confirmed, high risk advanced (FIGO stage III - IV) BRCA mutated high grade serous or high grade endometrioid ovarian cancer, primary peritoneal cancer and / or fallopian - tube cancer who have completed first line platinum based chemotherapy (intravenous or intraperitoneal). - Stage III patients must have had one attempt at optimal debulking surgery (upfront or interval debulking). Stage IV patients must have had either a biopsy and/or upfront or interval debulking surgery. - Documented mutation in BRCA1 or BRCA2 that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function). - Patients who have completed first line platinum (e.g. carboplatin or cisplatin), containing therapy (intravenous or intraperitoneal) prior to randomisation: - Patients must have, in the opinion of the investigator, clinical complete response or partial response and have no clinical evidence of disease progression on the post treatment scan or rising CA-125 level, following completion of this chemotherapy course. Patients with stable disease on the post-treatment scan at completion of first line platinum-containing therapy are not eligible for the study. - Patients must be randomized within 8 weeks of their last dose of chemotherapy Exclusion Criteria: - BRCA1 and/or BRCA2 mutations that are considered to be non detrimental (e.g. "Variants of uncertain clinical significance" or "Variant of unknown significance" or "Variant, favor polymorphism" or "benign polymorphism" etc). - Patients with early stage disease (FIGO Stage I, IIA, IIB or IIC) - Stable disease or progressive disease on the post-treatment scan or clinical evidence of progression at the end of the patient's first line chemotherapy treatment. - Patients where more than one debulking surgery has been performed before randomisation to the study. (Patients who, at the time of diagnosis, are deemed to be unresectable and undergo only a biopsy or oophorectomy but then go on to receive chemotherapy and interval debulking surgery are eligible). - Patients who have previously been diagnosed and treated for earlier stage ovarian, fallopian tube or primary peritoneal cancer. - Patients who have previously received chemotherapy for any abdominal or pelvic tumour, including treatment for prior diagnosis at an earlier stage for their ovarian, fallopian tube or primary peritoneal cancer. (Patients who have received prior adjuvant chemotherapy for localised breast cancer may be eligible, provided that it was completed more than three years prior to registration, and that the patient remains free of recurrent or metastatic disease). - Patients with synchronous primary endometrial cancer unless both of the following criteria are met: 1) stage <2 2) less than 60 years old at the time of diagnosis of endometrial cancer with stage IA or IB grade 1 or 2, or stage IA grade 3 endometrioid adenocarcinoma OR = 60 years old at the time of diagnosis of endometrial cancer with Stage IA grade 1 or 2 endometrioid adenocarcinoma. Patients with serous or clear cell adenocarcinoma or carcinosarcoma of the endometrium are not eligible.

Study Design


Intervention

Drug:
Olaparib 300mg tablets
Olaparib/placebo tablets p.o 300mg twice daily for up to 2 years or until objective radiological disease progression as per RECIST as assessed by the Investigator. Patients with evidence of stable disease (or those who have progressed), may continue on treatment beyond 2 years, if in the patient's best interest. Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.

Locations

Country Name City State
Australia Mercy Hospital for Women Heidelberg
Australia The Royal Womens Hospital Parkville
Australia Prince of Wales Hospital Randwick
Brazil Centro Diagnóstico Barretos Barretos
Brazil Hospital Araujo Jorge Goiânia
Brazil Centro de Novos Tratamentos Itajai Itajai
Brazil Hospital de Clinicas de Porto Alegre Porto Alegre
Brazil Irmandade da Santa Casa de Misericordia de Porto Alagre Porto Alegre
Brazil Hospital de Base São José do Rio Preto São José do Rio Preto
Brazil Centro de Referencia da Saude da Mulher São Paulo
Brazil Instituto do Câncer de São Paulo São Paulo
Canada Juravinski Cancer Centre Hamilton Ontario
Canada London Health Sciences Centre London Ontario
Canada CHUM - Hopital Norte-Dame Montreal Quebec
Canada Royal Victoria Hospital Montreal Quebec
Canada Hotel-Dieu de Quebec Quebec
Canada Princess Margaret Cancer Centre Toronto Ontario
Canada Sunnybrook Health Sciences Center Toronto Ontario
China Beijing Cancer Hospital Beijing
China The Tumor Hospital affiliated to China Medical Science Insti Beijing
China 1st Hospital of Jilin university Changchun
China Jilin Provincial Cancer Hospital Changchun
China Hunan Cancer Hospital Changsha
China West China Hospital Affiliated to Sichuan University Chengdu
China ChongQing Cancer Hospital Chongqing
China Research Site Guangzhou
China Women's Hospital, Zhejaing University School of Medicine Hangzhou
China The Tumour Hospital of Harbin Medical University Harbin
China Zhejiang Cancer Hospital, Huangzhou Huangzhou
China JINAN, Qi Lu Hosp. of SD Univ. Ji Nan
China Obstetris and Gynecology Hospital of Fudan University Shanghai
China Shanghai Cancer Hospital of Fudan University Shanghai
China The First Affiliated Hospital of Soochow Universit Suzhou
China First affiliated hospital college of XianJiaotong University Xian
France Institut Bergonie Bordeaux
France CAC François Baclesse Caen Cedex
France 69LYON, C Bérard, Onco Lyon Cedex 08
France Centre Catherine de Sienne Nantes,
France 75PARIS, H Tenon, Onco Paris
France Centre Alexis Vautrin Vandoeuvre Les Nancy
France Institut Gustave Roussy Villejuif Cedex
Israel Rambam Health Care Campus Haifa
Israel Sapir Medical Centre Kfar Saba
Israel Rabin MC Petach Tikva
Israel Chaim Sheba Medical Centre Tel Hashomer
Israel Tel-Aviv Sourkasy Medical Center Tel-Aviv
Italy Bari- Istituto Tumori Giovanni Paolo II Bari
Italy Azienda Ospedaliera "Cannizzaro" Catania
Italy Istituto Europeo di Oncologia Milano
Italy Istituto Nazionale Per Cura Tumori - Milano Milano
Italy Istituto Nazionale Tumori Fondazione Pascale Napoli
Italy Istituto Oncologico Veneto Irccs Padova
Italy Istituto Regina Elena-Polo Oncologico Ifo Roma
Italy Policlinico Universitario A. Gemelli Roma
Japan Hyogo CC Akashi-shi
Japan National Cancer Center Hosp Chuo-ku
Japan NHO Kyushu CC Fukuoka
Japan Saitama Med. Univ. Int. Med. C Hidaka-shi
Japan NHO Shikoku Cancer Center Matsuyama-shi
Japan Niigata Univ. Med. Dent. Niigata-shi
Japan Hokkaido University Hospital Sapporo-shi
Japan Shizuoka Cancer Center Sunto-gun
Korea, Republic of National Cancer Center Goyang-si
Korea, Republic of Asan Medical Center Seoul
Korea, Republic of Gangnam Severance Hospital Seoul
Korea, Republic of Korea Cancer Center Hospital Seoul
Korea, Republic of Samsung Medical Center Seoul
Korea, Republic of Seoul National University Hospital Seoul
Netherlands Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital Amsterdam
Netherlands Maastricht Universitair Medisch Centrum Maastricht
Poland Niepubliczny Zaklad Opieki Zdrowotnej Innowacyjna Medycyna Grzepnica
Poland SPZOZ MSWiA z Warminsko-Mazurskim Centrum Onkologii Olsztyn
Poland Wojewódzki Szpital Specjalistyczny w Olsztynie Olsztyn
Poland Centrum Onkologii-Instytut im. Marii Sklodowskiej-Curie Warszawa
Poland Szpital Specjalistyczny im. Swietej Rodziny SPZOZ Warszawa
Russian Federation Udmurtia Republic Clinical Oncology Center Izhevsk
Russian Federation Chemotherapy Department, Russian Cancer Research Centre Moscow
Russian Federation State Institution of Heath Omsk Regional Oncology Dispensary Omsk
Russian Federation Cancer Research Institute Saint Petersburg
Russian Federation St.Petersburg City Oncology Dispensary, Dept. Gynecology Saint Petersburg
Russian Federation Leningrad Regional Oncology Dispensary St.Petersburg
Russian Federation Research Institute of Oncology RAMS Tomsk
Spain Barcelona,H.Vall d´Hebrón,Oncología Barcelona
Spain Córdoba,H.Reina Sofía,Oncología Córdoba
Spain H.Llobregat,ICO-Duran i Reynals,Oncología Hospitalet deLlobregat(Barcelo
Spain Madrid, MD Anderson, Oncología Madrid
Spain Madrid,H.U.La Paz,Oncología Madrid
Spain Valencia, IVO, Oncología Valencia
Spain Valencia,H.C.U.Valencia,Oncología Valencia
United Kingdom City Hospital, Birmingham, Cancer Trials Team Birmingham
United Kingdom Addenbrooke's Hospital Cambridge
United Kingdom Arden Cancer Centre Coventry
United Kingdom Edinburgh Cancer Research UK Centre Edinburgh
United Kingdom Cancer Research UK and UCL Cancer Trials Centre London
United Kingdom Royal Marsden Hospital London
United Kingdom Royal Marsden Hospital and Institute of Cancer Research Sutton
United States Abington Memorial Hospital Abington Pennsylvania
United States Women's Cancer Care Associates Albany New York
United States University of New Mexico Albuquerque New Mexico
United States McFarland Clinic, P.C. Ames Iowa
United States Providence Cancer Center Anchorage Alaska
United States Hope Women's Cancer Centers Asheville North Carolina
United States Northside Hospital Atlanta Georgia
United States University of Colorado Aurora Colorado
United States Greater Baltimore Medical Center Baltimore Maryland
United States Johns Hopkins Baltimore Maryland
United States Walter Reed National Military Medical Center Bethesda Maryland
United States St. Luke's University Health Network Bethlehem Pennsylvania
United States Beth Israel Deaconess Medical Center Boston Massachusetts
United States Dana Farber Cancer Institute Boston Massachusetts
United States Massachusetts General Hospital Boston Massachusetts
United States Roswell Park Cancer Institute Buffalo New York
United States MD Anderson at Cooper Cancer Center Camden New Jersey
United States Aultman Hospital Canton Ohio
United States UNC Chapel Hill Chapel Hill North Carolina
United States Levine Cancer Institute Charlotte North Carolina
United States University of Virginia Charlottesville Virginia
United States Northwestern University Chicago Illinois
United States Univ Chicago Medical Center Chicago Illinois
United States Cleveland Clinic Cancer Center at Fairview Hospital Cleveland Ohio
United States Cleveland Clinic Foundation Cleveland Ohio
United States University Hospital Case Medical Center Cleveland Ohio
United States South Carolina Oncology Associates, PA Columbia South Carolina
United States Research Site Columbus Ohio
United States University of Texas Southwestern Medical Center Dallas Texas
United States Henry Ford Health System Detroit Michigan
United States Duke University Medical Center Durham North Carolina
United States Minnesota Oncology Hematology, PA Edina Minnesota
United States Sanford Roger Maris Cancer Center Fargo North Dakota
United States Univ of Connecticut Health Center Farmington Connecticut
United States Northeast Georgia Medical Center Gainesville Georgia
United States Gynecologic Oncology of West MI, PLLC Grand Rapids Michigan
United States Aurora Baycare Medical Center Green Bay Wisconsin
United States John Theurer Cancer Center Hackensack New Jersey
United States The Queen's Medical Center Honolulu Hawaii
United States University of Hawaii Honolulu Hawaii
United States MD Anderson Cancer Center Houston Texas
United States University of Texas Health Science Center of Houston Houston Texas
United States Clearview Cancer Institute Huntsville Alabama
United States Indiana University Indianapolis Indiana
United States St. Vincent Hospital & Health Care Center Indianapolis Indiana
United States University of Mississippi Medical Center Jackson Mississippi
United States Kettering Medical Center Kettering Ohio
United States Womens Cancer Center of Nevada Las Vegas Nevada
United States Cedars-Sinai Medical Center Los Angeles California
United States University of California, Los Angeles Los Angeles California
United States Norton Cancer Institute Research Louisville Kentucky
United States University of Wisconsin-Madison Madison Wisconsin
United States Hillcrest Hospital Cancer Center Mayfield Heights Ohio
United States Froedtert Memorial Hospital Milwaukee Wisconsin
United States Northern Indiana Cancer Research Consortium Mishawaka Indiana
United States Smilow Cancer Hospital at Yale New Haven New Haven Connecticut
United States Memorial Sloan Kettering Cancer Center New York New York
United States Mount Sinai Medical Center - New York New York New York
United States Perlmutter Cancer Center New York New York
United States Virginia Oncology Associates Norfolk Virginia
United States Kaiser Permanente Oakland California
United States Peggy and Charles Stephenson Cancer Center Oklahoma City Oklahoma
United States Missouri Valley Cancer Consortium CCOP Omaha Nebraska
United States Nebraska Methodist Hospital Omaha Nebraska
United States Florida Hospital Cancer Institute Orlando Florida
United States Gynecologic Cancer Center Orlando Florida
United States Advocate Lutheran General Hospital Park Ridge Illinois
United States The University of Pennsylvania Philadelphia Pennsylvania
United States St. Joseph's Hospital & Medical Center Phoenix Arizona
United States Women and Infants Hospital Providence Rhode Island
United States Carilion Clinic Gynecological Oncology Roanoke Virginia
United States Mayo Clinic - Rochester, MN Rochester Minnesota
United States Kaiser Permanente Roseville California
United States Washington University School of Medicine Saint Louis Missouri
United States Nancy N. & J.C. Lewis Cancer and Research Pavillion Savannah Georgia
United States Maine Medical Partners Scarborough Maine
United States Avera Cancer Institute Sioux Falls South Dakota
United States Sanford Clinic Women's Health Sioux Falls South Dakota
United States Stanford Women's Cancer Center Stanford California
United States H Lee Moffitt Cancer Center and Research Institute Tampa Florida
United States Babak Edraki Walnut Creek California

Sponsors (4)

Lead Sponsor Collaborator
AstraZeneca GOG Foundation, Merck Sharp & Dohme LLC, Myriad Genetic Laboratories, Inc.

Countries where clinical trial is conducted

United States,  Australia,  Brazil,  Canada,  China,  France,  Israel,  Italy,  Japan,  Korea, Republic of,  Netherlands,  Poland,  Russian Federation,  Spain,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression Free Survival (PFS) Using Investigator Assessment According to Modified Response Evaluation Criteria in Solid Tumours (RECIST 1.1) To determine the efficacy by progression free survival (PFS) using investigator assessment according to modified Response Evaluation Criteria in Solid Tumours (RECIST 1.1) of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy. Radiologic scans performed at baseline then every 12 weeks up to 156 weeks, then every 24 weeks thereafter until objective radiological disease progression. DCO: 17 May 2018
Secondary Efficacy in Patients Following First Line Platinum Based Chemotherapy by Assessment of Overall Survival To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of overall survival (OS). Reports results of a pre-specified interim analysis; results for final OS analysis (235 OS events) anticipated 2029. Assessed every 4 weeks until treatment discontinues (up to a max of 156 weeks), then as per protocol. Analysis performed with DCO: 17May2018. Further analyses will be performed at 7 years (descriptive), after 206 events and after 60% maturity.
Secondary Efficacy in Patients Following First Line Platinum Based Chemotherapy by Assessment of Time to Earliest Progression by RECIST or Cancer Antigen (CA-125) or Death To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time to earliest progression by RECIST or Cancer Antigen-125 (CA-125) or death CA-125 performed at baseline + every 4 weeks. Radiologic scans performed at baseline + every 12 weeks up to 156 weeks, then every 24 weeks until objective radiological disease progression. DCO:17May2018
Secondary Efficacy in Patients Following First Line Platinum Based Chemotherapy by Assessment of Time From Randomization to Second Progression To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time from randomisation to second progression (PFS2) Following first progression disease then assessed per local practice every 12 weeks until second progression.
Secondary Change From Baseline in Health-Related Quality of Life (HRQoL) as Assessed by the the Trial Outcome Index (TOI) of the Functional Assessment of Cancer Therapy - Ovarian (FACT-O) To compare the effects of olaparib maintenance monotherapy compared to placebo on Health-related Quality of Life (HRQoL) as assessed by the trial outcome index (TOI) of the Functional Assessment of Cancer Therapy - Ovarian (FACT-O) in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy. The TOI ranges from 0-100 and a higher score indicates a higher HRQoL. Questionnaires will be given to the patient at baseline, at Day 29 and then every 12 weeks for 156 weeks, then every 24 weeks or until the data cut off for the PFS analysis, change in TOI over 24 months reported
Secondary Efficacy in Patients Following First Line Platinum Based Chemotherapy by Assessment of Time to First Subsequent Therapy or Death (TFST) To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time from randomisation to first subsequent therapy or death (TFST). Reports results of a pre-specified interim analysis; final analysis results will later be added at time of final OS analysis (anticipated 2029). Assessed every 12 weeks following treatment discontinuation. Analysis performed with DCO: 17May2018. Further analyses will be performed at 7 years (descriptive), after 206 events and after 60% maturity.
Secondary Efficacy in Patients Following First Line Platinum Based Chemotherapy by Assessment of Time to Second Subsequent Therapy or Death (TSST) To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time from randomisation to second subsequent therapy or death (TSST). Reports results of a pre-specified interim analysis; final analysis results will later be added at time of final OS analysis (anticipated 2029). Assessed every 12 weeks following treatment discontinuation. Analysis performed with DCO: 17May2018. Further analyses will be performed at 7 years (descriptive), after 206 events and after 60% maturity.
Secondary Efficacy in Patients Following First Line Platinum Based Chemotherapy by Assessment of Time From Randomization to Study Treatment Discontinuation or Death (TDT) To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time from randomisation to study treatment discontinuation or death (TDT). Reports results of a pre-specified interim analysis; final analysis results will later be added at time of final OS analysis (anticipated 2029). Time elapsed from randomization to study treatment discontinuation or death. Analysis performed with DCO: 17May2018. Further analyses will be performed at 7 years (descriptive), after 206 events and after 60% maturity.
Secondary Efficacy in Patients With a Deleterious or Suspected Deleterious Variant in Either of the BRCA Genes by Assessment of PFS To assess efficacy of olaparib in patients identified as having a deleterious or suspected deleterious variant in either of the BRCA genes using variants identified with current and potential future BRCA mutation assays (gene sequencing and large rearrangement analysis) Radiologic scans performed at baseline then every 12 weeks for the first 156 weeks, then every 24 weeks thereafter, assessed until disease progression. Analysis of data assessed up to a maximum of 54 months.
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03611179 - Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian Cancer Phase 2
Not yet recruiting NCT06055348 - SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer Phase 1/Phase 2
Completed NCT04135521 - Dose-dense Chemotherapy Versus Intraperitoneal Chemotherapy as First-line Chemotherapy in Advanced Ovarian Cancer
Completed NCT01462149 - Efficacy Study of Neoadjuvant Chemotherapy to Treat Advanced Ovarian Cancer Phase 2
Terminated NCT03292172 - A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer Phase 1
Not yet recruiting NCT05794659 - Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer Phase 2
Completed NCT04360629 - Efficacy and Safety of Tranexamic Acid in Cytoreductive Surgery for Ovarian Cancer N/A
Completed NCT00516724 - Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel Phase 1
Completed NCT03158935 - The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial Phase 1
Completed NCT05775549 - A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer
Active, not recruiting NCT03737643 - Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients Phase 3
Completed NCT01290471 - Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors Phase 1
Recruiting NCT04862325 - SOPHIE Trial: Surgery in Ovarian Cancer With PreHabilitation In ERAS N/A
Completed NCT01989546 - Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations Phase 1/Phase 2
Recruiting NCT04556539 - Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer Phase 2
Completed NCT03161132 - Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin Phase 2
Active, not recruiting NCT04065009 - The IPLA-OVCA Trial, Intra-Peritoneal Local Anaesthetics in Ovarian Cancer Phase 3
Not yet recruiting NCT05924776 - Plasmodium Immunotherapy for Advanced Ovarian Cancer Phase 2/Phase 3
Active, not recruiting NCT03878849 - Investigation of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP® Phase 2